SanBio will continue development of SB623 cell therapy for chronic cerebral hemorrhage

SB623is proprietary product of SanBio, bone marrow-derived mesenchymal stem cells that have been genetically engineered to express the intracellular domain of Notch-1. When injected into neural tissue, SB623 cells seem to reverse neural damage.

SanBio news release, January 19, 2019


Most popular posts: